Based on that AKT1, MAPK3 and ESR1 were included in cancer pathways, as well as AKT1 and MAPK3 included in the PI3K-Akt signaling pathway, the docking results again confirmed the prediction of network pharmacology. This evidence concerns the gene MAPK3 and cancer.